<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2022-16-7-76-83</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-6864</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Заболевания билиарной системы и печени</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Liver diseases</subject></subj-group></article-categories><title-group><article-title>Дискуссионные возможности биохимических маркеров функции печени у пациентов с алкогольным циррозом печени</article-title><trans-title-group xml:lang="en"><trans-title>Debating capabilities of biochemical markers of liver function in patients with alcoholic liver cirrhosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2129-8542</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иконникова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ikonnikova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иконникова Каролина Андреевна - аспирант кафедры клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2.</p></bio><bio xml:lang="en"><p>Karolina A. Ikonnikova - Postgraduate Student, Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University).</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991.</p></bio><email xlink:type="simple">karolin.ikonnikova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8677-1946</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ерощенко</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Eroshchenko</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ерощенко Николай Николаевич - химик-эксперт Центра биоаналитических исследований и молекулярного дизайна Научно-технологического парка биомедицины.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2.</p></bio><bio xml:lang="en"><p>Nikolay N. Eroshchenko - Expert-Chemist of the Center for Bioanalytical Research and Molecular Design of the Scientific and Technological Park of Biomedicine, Sechenov First Moscow State Medical University (Sechenov University).</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991.</p></bio><email xlink:type="simple">eroshchenko_n_n@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0535-2916</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дроздов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Drozdov</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дроздов Владимир Николаевич - доктор медицинских наук, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2.</p></bio><bio xml:lang="en"><p>Vladimir N. Drozdov - Dr. Sci. (Med.), Professor of the Department of Clinical  Pharmacology  and  Propaedeutics  of  Internal  Diseases, Sechenov First Moscow State Medical University (Sechenov University).</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991.</p></bio><email xlink:type="simple">drozdov_v_n@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6589-7654</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ших</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shikh</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ших Евгения Валерьевна - доктор медицинских наук, профессор, заведующая кафедрой клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2.</p></bio><bio xml:lang="en"><p>Evgenia V. Shikh - Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sechenov  First Moscow State Medical University (Sechenov University).</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991.</p></bio><email xlink:type="simple">shikh_e_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7163-7119</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сереброва</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Serebrova</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сереброва Светлана Юрьевна - доктор медицинских наук, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней, ПМГМУ им. И.М. Сеченова (Сеченовский Университет); главный научный сотрудник Центра клинической фармакологии, НЦЭСМП.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2; 127051, Москва, Петровский бульвар, д. 8, стр. 2.</p></bio><bio xml:lang="en"><p>Svetlana Yu. Serebrova - Dr. Sci. (Med.), Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University); Chief Researcher of the Center  for Clinical Pharmacology, Scientific Centre for Expert Evaluation of Medicinal Products.</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991; 8, Bldg. 2, Petrovsky Boulevard, Moscow, 127051.</p></bio><email xlink:type="simple">svetaserebrova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет); Научный центр экспертизы средств медицинского применения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University); Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>14</day><month>05</month><year>2022</year></pub-date><volume>0</volume><issue>7</issue><fpage>76</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Иконникова К.А., Ерощенко Н.Н., Дроздов В.Н., Ших Е.В., Сереброва С.Ю., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Иконникова К.А., Ерощенко Н.Н., Дроздов В.Н., Ших Е.В., Сереброва С.Ю.</copyright-holder><copyright-holder xml:lang="en">Ikonnikova K.A., Eroshchenko N.N., Drozdov V.N., Shikh E.V., Serebrova S.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/6864">https://www.med-sovet.pro/jour/article/view/6864</self-uri><abstract><sec><title>Введение</title><p>Введение. Диагностика алкогольного поражения печени ограничена  отсутствием  инструмента  достоверного  выявления связи настоящего ухудшения состояния пациента с употреблением алкоголя или с другими причинами.</p><p>Цель – провести сравнительную оценку клинико-диагностической значимости биохимических показателей функции печени и их расчетных производных в качестве биомаркеров алкоголя у пациентов с алкогольным циррозом печени.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В обсервационное исследование включены 112 совершеннолетних мужчин с алкогольным циррозом печени. У пациентов оценивались тяжесть цирроза печени по шкале Чайлд – Пью, уровень фосфатидилэтанола и биохимических показателей функции печени. Проанализирована связь употребления алкоголя с изменением показателей функции печени с определением их чувствительности и специфичности.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с циррозом печени класса B по Чайлд – Пью, употреблявших алкоголь, отмечались более высокие уровни альбумина, гамма-глутамилтрансферазы (ГГТ) и более низкие значения креатинина, прямого и общего билирубина, мочевины и АЧТВ по сравнению с пациентами, не употребляющими алкоголь (p &lt; 0,05). У пациентов, употребляющих алкоголь, с циррозом печени класса С – более высокий уровень АЛТ по сравнению с воздерживающимися (p &lt; 0,05). Оказались статистически значимыми отношения между фактом употребления по фосфатидилэтанолу и отношением ГГТ пациентов к ГГТнорм., а также между отношением ГГТ к щелочной фосфатазе и степенью повышения ГГТ. Для оценки факта употребления алкоголя наибольшей чувствительностью обладает ГГТ &gt; 65 МЕ/л (75,5%), наибольшей специфичностью – показатель отношения ГГТ пациента к нормальному значению ГГТ &gt; 2 (82,9%).</p></sec><sec><title>Вывод</title><p>Вывод. По сравнению с известными 100%-й чувствительностью и более чем 92%-й специфичностью фосфатидилэтанола как маркера алкоголя среди показателей функции печени и их производных наибольшей чувствительностью/специфичностью обладают ГГТ &gt; 65 МЕ/л (соответственно 75,5 и 65%) и ГГТнорм. &gt; 2 (соответственно 37,7 и 82,9%), что позволяет использовать совокупность данных параметров как показатель употребления алкоголя в рутинной практике.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. The diagnosis of alcohol-related liver disease is limited by the lack of a tool to reliably identify whether the present deterioration in the patient’s condition is due to alcohol consumption or other causes.</p></sec><sec><title>Purpose</title><p>Purpose. to conduct a comparative assessment of the clinical and diagnostic significance of liver function biochemical indicators (AST, ALT, GGT, ALP) and their calculated derivatives (AST/ALT, GGT/ALP, GGT/GGTn, ALP/ALPn) as markers of alcohol consumption in patients with alcoholic liver cirrhosis.</p></sec><sec><title>Material and methods</title><p>Material and methods. The observational study included 112 men over 18 years of age with alcohol-related liver cirrhosis. The patients were assessed the severity of liver cirrhosis according to the Child-Pugh scale, performed general and biochemical blood tests, coagulation test, assessment of the fact of alcohol consumption by the level of phosphatidylethanol. An analysis was made of the relationship between alcohol consumption and changes in laboratory parameters of liver function, with the determination of their sensitivity and specificity.</p></sec><sec><title>Results</title><p>Results. Patients with Child-Pugh B cirrhosis who consumed alcohol on phosphatidylethanol had higher levels of plasma albumin, GGT, and lower values of creatinine, direct and total bilirubin, urea, and aPTT compared with patients who did not drink alcohol (p &lt; 0.05). Alcohol-drinking patients with class C cirrhosis have higher ALT levels compared with abstinent patients with the same severity of cirrhosis (p &lt; 0.05). The relationship between the fact of alcohol consumption, determined by the level of phosphatidylethanol, and the ratio of GGT of patients to the normal GGT value, as well as between the ratio of GGT to alkaline phosphatase and the degree of increase in GGT, turned out to be statistically significant. To assess the fact of alcohol consumption, the level of serum GGT &gt; 65 IU/ l (75.5%) has the highest sensitivity, the highest specificity is the ratio of the patient’s GGT to the normal value of GGT &gt; 2 (82.9%).</p></sec><sec><title>Conclusion</title><p>Conclusion. Compared with the known 100% sensitivity and &gt; 92% specificity of Peth as a alcohol biomarker, among the biochemical indicators of liver function and their calculated derivatives, GGT &gt; 65 IU/l have the greatest sensitivity or specificity (respectively, 75.5% and 65%) and GGTnorm. &gt; 2 (37.7% and 82.9%, respectively), which makes it possible to use the totality of these parameters as an indicator of the continued impact on the patient of the main etiological factor of alcohol-related liver cirrhosis in the routine practice of most medical organizations of the Russian Federation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>алкогольный цирроз печени</kwd><kwd>фосфатидилэтанол</kwd><kwd>биомаркеры алкоголя</kwd><kwd>аспартатаминотрансфераза</kwd><kwd>аланинаминотрансфераза</kwd><kwd>гамма-глутамилтрансфераза</kwd><kwd>щелочная фосфатаза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>alcohol‐associated liver cirrhosis</kwd><kwd>phosphatidylethanol</kwd><kwd>alcohol biomarkers</kwd><kwd>aspartate aminotransferase</kwd><kwd>alanine aminotransferase</kwd><kwd>gamma-glutamyl transpeptidase</kwd><kwd>alkaline phosphatase</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–1035. https://doi.org/10.1016/s0140-6736(18)31310-2.</mixed-citation><mixed-citation xml:lang="en">GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–1035. https://doi.org/10.1016/s0140-6736(18)31310-2.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rumgay H., Shield K., Charvat H., Ferrari P., Sornpaisarn B., Obot I. et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021;22(8):1071–1080. https://doi.org/10.1016/S1470-2045(21)00279-5.</mixed-citation><mixed-citation xml:lang="en">Rumgay H., Shield K., Charvat H., Ferrari P., Sornpaisarn B., Obot I. et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol. 2021;22(8):1071–1080. https://doi.org/10.1016/S1470-2045(21)00279-5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Сиволап Ю.П., Луньков В.Д., Жаркова М.С., Масленников Р.В. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20–40. Режим доступа: https://www.gastro-j.ru/jour/article/view/190.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Mayevskaya M.V., Pavlov C.S., Sivolap Yu.P., Lunkov V.D., Zharkova M.S., Maslennikov R.V. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):20–40. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/190.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ginès P., Krag A., Abraldes J.G., Solà E., Fabrellas N., Kamath P.S. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. https://doi.org/10.1016/S0140-6736(21)01374-X.</mixed-citation><mixed-citation xml:lang="en">Ginès P., Krag A., Abraldes J.G., Solà E., Fabrellas N., Kamath P.S. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. https://doi.org/10.1016/S0140-6736(21)01374-X.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hagström H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Curr Hepatol Rep. 2017;16(2):152–157. https://doi.org/10.1007/s11901-017-0343-0.</mixed-citation><mixed-citation xml:lang="en">Hagström H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Curr Hepatol Rep. 2017;16(2):152–157. https://doi.org/10.1007/s11901-017-0343-0.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Szabo G., Kamath P.S., Shah V.H., Thursz M., Mathurin P. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019;69(5):2271–2283. https://doi.org/10.1002/hep.30369.</mixed-citation><mixed-citation xml:lang="en">Szabo G., Kamath P.S., Shah V.H., Thursz M., Mathurin P. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019;69(5):2271–2283. https://doi.org/10.1002/hep.30369.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dasgupta A. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Elsevier; 2015. 312 p.</mixed-citation><mixed-citation xml:lang="en">Dasgupta A. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Elsevier; 2015. 312 p.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Баринская Т.О., Смирнов А.В., Саломатин Е.М., Шаев А.И. Кинетика этанола в биологических средах. Судебно­медицинская экспертиза. 2006;49(1):27–32. Режим доступа: https://www.elibrary.ru/item.asp?id=9186951.</mixed-citation><mixed-citation xml:lang="en">Barinskaya T.O., Smirnov A.V., Salomatin E.M., Shaev A.I. Kinetics of ethanol in biological environment. Sudebno­Meditsinskaya Ekspertisa. 2006;49(1):27–32. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=9186951.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption – II. Addiction. 1993;88(6):791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x.</mixed-citation><mixed-citation xml:lang="en">Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption – II. Addiction. 1993;88(6):791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bush B., Shaw S., Cleary P., Delbanco T.L., Aronson M.D. Screening for alcohol abuse using the CAGE questionnaire. Am J Med. 1987;82(2):231–235. https://doi.org/10.1016/0002-9343(87)90061-1.</mixed-citation><mixed-citation xml:lang="en">Bush B., Shaw S., Cleary P., Delbanco T.L., Aronson M.D. Screening for alcohol abuse using the CAGE questionnaire. Am J Med. 1987;82(2):231–235. https://doi.org/10.1016/0002-9343(87)90061-1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lange S., Shield K., Monteiro M., Rehm J. Facilitating Screening and Brief Interventions in Primary Care: A Systematic Review and Meta-Analysis of the AUDIT as an Indicator of Alcohol Use Disorders. Alcohol Clin Exp Res. 2019;43(10):2028–2037. https://doi.org/10.1111/acer.14171.</mixed-citation><mixed-citation xml:lang="en">Lange S., Shield K., Monteiro M., Rehm J. Facilitating Screening and Brief Interventions in Primary Care: A Systematic Review and Meta-Analysis of the AUDIT as an Indicator of Alcohol Use Disorders. Alcohol Clin Exp Res. 2019;43(10):2028–2037. https://doi.org/10.1111/acer.14171.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Павлов А.И. Алкогольная болезнь печени: диагностика и лечение в многопрофильном стационаре. Эффективная фармакотерапия. 2013;(4):30–37. Режим доступа: https://umedp.ru/articles/alkogolnaya_bolezn_pecheni_diagnostika_i_lechenie_v_mnogoprofilnom_statsionare.html.</mixed-citation><mixed-citation xml:lang="en">Pavlov A.I. Alcoholic liver disease: diagnosis and management in general hospital. Effective Pharmacotherapy. 2013;(4):30–37. (In Russ.) Available at: https://umedp.ru/articles/alkogolnaya_bolezn_pecheni_diagnostika_i_lechenie_v_mnogoprofilnom_statsionare.html.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Woźniak M.K., Wiergowski M., Namieśnik J., Biziuk M. Biomarkers of Alcohol Consumption in Body Fluids – Possibilities and Limitations of Application in Toxicological Analysis. Curr Med Chem. 2019;26(1):177–196. https://doi.org/10.2174/0929867324666171005111911.</mixed-citation><mixed-citation xml:lang="en">Woźniak M.K., Wiergowski M., Namieśnik J., Biziuk M. Biomarkers of Alcohol Consumption in Body Fluids – Possibilities and Limitations of Application in Toxicological Analysis. Curr Med Chem. 2019;26(1):177–196. https://doi.org/10.2174/0929867324666171005111911.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dong M.H., Bettencourt R., Brenner D.A., Barrett-Connor E., Loomba R. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol. 2012;10(3):285–290.e1. https://doi.org/10.1016/j.cgh.2011.10.014.</mixed-citation><mixed-citation xml:lang="en">Dong M.H., Bettencourt R., Brenner D.A., Barrett-Connor E., Loomba R. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol. 2012;10(3):285–290.e1. https://doi.org/10.1016/j.cgh.2011.10.014.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">England K., Thorne C., Pembrey L., Tovo P.A., Newell M.L. Age- and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr. 2009;49(1):71–77. https://doi.org/10.1097/MPG.0b013e31818fc63b.</mixed-citation><mixed-citation xml:lang="en">England K., Thorne C., Pembrey L., Tovo P.A., Newell M.L. Age- and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr. 2009;49(1):71–77. https://doi.org/10.1097/MPG.0b013e31818fc63b.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart S.H. Phosphatidylethanol and Alcohol Use in Liver Disease Patients. In: Patel V., Preedy V. (eds.). Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht; 2017, pp. 527–544. https://doi.org/10.1007/978-94-007-7675-3_18.</mixed-citation><mixed-citation xml:lang="en">Stewart S.H. Phosphatidylethanol and Alcohol Use in Liver Disease Patients. In: Patel V., Preedy V. (eds.). Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht; 2017, pp. 527–544. https://doi.org/10.1007/978-94-007-7675-3_18.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Conigrave K.M., Davies P., Haber P., Whitfield J.B. Traditional markers of excessive alcohol use. Addiction. 2003;98(2 Suppl.):31–43. https://doi.org/10.1046/j.1359-6357.2003.00581.x.</mixed-citation><mixed-citation xml:lang="en">Conigrave K.M., Davies P., Haber P., Whitfield J.B. Traditional markers of excessive alcohol use. Addiction. 2003;98(2 Suppl.):31–43. https://doi.org/10.1046/j.1359-6357.2003.00581.x.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ulwelling W., Smith K. The PEth Blood Test in the Security Environment: What it is; Why it is Important; and Interpretative Guidelines. J Forensic Sci. 2018;63(6):1634–1640. https://doi.org/10.1111/1556-4029.13874.</mixed-citation><mixed-citation xml:lang="en">Ulwelling W., Smith K. The PEth Blood Test in the Security Environment: What it is; Why it is Important; and Interpretative Guidelines. J Forensic Sci. 2018;63(6):1634–1640. https://doi.org/10.1111/1556-4029.13874.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Celli R., Zhang X. Pathology of Alcoholic Liver Disease. J Clin Transl Hepatol. 2014;2(2):103–109. https://doi.org/10.14218/JCTH.2014.00010.</mixed-citation><mixed-citation xml:lang="en">Celli R., Zhang X. Pathology of Alcoholic Liver Disease. J Clin Transl Hepatol. 2014;2(2):103–109. https://doi.org/10.14218/JCTH.2014.00010.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen V.L., Haber P.S., Seth D. Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini Review). Alcohol Clin Exp Res. 2018;42(2):238–243. https://doi.org/10.1111/acer.13558.</mixed-citation><mixed-citation xml:lang="en">Nguyen V.L., Haber P.S., Seth D. Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini Review). Alcohol Clin Exp Res. 2018;42(2):238–243. https://doi.org/10.1111/acer.13558.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Crabb D.W., Im G.Y., Szabo G., Mellinger J.L., Lucey M.R. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–333. https://doi.org/10.1002/hep.30866.</mixed-citation><mixed-citation xml:lang="en">Crabb D.W., Im G.Y., Szabo G., Mellinger J.L., Lucey M.R. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–333. https://doi.org/10.1002/hep.30866.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Andresen-Streichert H., Beres Y., Weinmann W., Schröck A., Müller A., Skopp G. et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017;30(6):611–620. https://doi.org/10.1111/tri.12949.</mixed-citation><mixed-citation xml:lang="en">Andresen-Streichert H., Beres Y., Weinmann W., Schröck A., Müller A., Skopp G. et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transpl Int. 2017;30(6):611–620. https://doi.org/10.1111/tri.12949.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Iffland R. New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Alcohol Alcohol. 1996;31(6):619–620. https://doi.org/10.1093/oxfordjournals.alcalc.a008201.</mixed-citation><mixed-citation xml:lang="en">Iffland R. New ways to use biochemical indicators of alcohol abuse to regrant licences in a fairer manner after drunken driving in Germany. Alcohol Alcohol. 1996;31(6):619–620. https://doi.org/10.1093/oxfordjournals.alcalc.a008201.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sillanaukee P., Massot N., Jousilahti P., Vartiainen E., Poikolainen K., Olsson U., Alho H. Enhanced clinical utility of gamma-CDT in a general population. Alcohol Clin Exp Res. 2000;24(8):1202–1206. Available at: https://pubmed.ncbi.nlm.nih.gov/10968658/.</mixed-citation><mixed-citation xml:lang="en">Sillanaukee P., Massot N., Jousilahti P., Vartiainen E., Poikolainen K., Olsson U., Alho H. Enhanced clinical utility of gamma-CDT in a general population. Alcohol Clin Exp Res. 2000;24(8):1202–1206. Available at: https://pubmed.ncbi.nlm.nih.gov/10968658/.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kunutsor S.K. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36(12):1723–1734. https://doi.org/10.1111/liv.13221.</mixed-citation><mixed-citation xml:lang="en">Kunutsor S.K. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36(12):1723–1734. https://doi.org/10.1111/liv.13221.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Whitehead T.P., Robinson D., Allaway S.L. The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: a dose-related study in men. Ann Clin Biochem. 1996;33(Pt 6):530–535. https://doi.org/10.1177/000456329603300607.</mixed-citation><mixed-citation xml:lang="en">Whitehead T.P., Robinson D., Allaway S.L. The effects of cigarette smoking and alcohol consumption on serum liver enzyme activities: a dose-related study in men. Ann Clin Biochem. 1996;33(Pt 6):530–535. https://doi.org/10.1177/000456329603300607.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda M., Maki T., Yin G., Kawate H., Adachi M., Ohnaka K. et al. Relation of coffee consumption and serum liver enzymes in Japanese men and women with reference to effect modification of alcohol use and body mass index. Scand J Clin Lab Invest. 2010;70(3):171–179. https://doi.org/10.3109/00365511003650165.</mixed-citation><mixed-citation xml:lang="en">Ikeda M., Maki T., Yin G., Kawate H., Adachi M., Ohnaka K. et al. Relation of coffee consumption and serum liver enzymes in Japanese men and women with reference to effect modification of alcohol use and body mass index. Scand J Clin Lab Invest. 2010;70(3):171–179. https://doi.org/10.3109/00365511003650165.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Klatsky A.L., Morton C., Udaltsova N., Friedman G.D. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166(11):1190–1195. https://doi.org/10.1001/archinte.166.11.1190.</mixed-citation><mixed-citation xml:lang="en">Klatsky A.L., Morton C., Udaltsova N., Friedman G.D. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166(11):1190–1195. https://doi.org/10.1001/archinte.166.11.1190.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Urso C., Brucculeri S., Caimi G. Marked elevation of transaminases and pancreatic enzymes in severe malnourished male with eating disorder. Clin Ter. 2013;164(5):e387–e391. https://doi.org/10.7417/ct.2013.1619.</mixed-citation><mixed-citation xml:lang="en">Urso C., Brucculeri S., Caimi G. Marked elevation of transaminases and pancreatic enzymes in severe malnourished male with eating disorder. Clin Ter. 2013;164(5):e387–e391. https://doi.org/10.7417/ct.2013.1619.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lofthus D.M., Stevens S.R., Armstrong P.W., Granger C.B., Mahaffey K.W. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coron Artery Dis. 2012;23(1):22–30. https://doi.org/10.1097/mca.0b013e32834e4ef1.</mixed-citation><mixed-citation xml:lang="en">Lofthus D.M., Stevens S.R., Armstrong P.W., Granger C.B., Mahaffey K.W. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coron Artery Dis. 2012;23(1):22–30. https://doi.org/10.1097/mca.0b013e32834e4ef1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
